1 Urate, blood pressure and cardiovascular disease: updated 2 evidence from Mendelian randomization and meta-analysis 3 of clinical trials

4
5 Gill *et al.* Urate, blood pressure and cardiovascular disease

6
7 Dipender Gill BMBCh PhD^{1*}, Alan C. Cameron MBChB PhD^{2*}, Stephen Burgess PhD^{3,4}, Xue Li PhD⁵,
8 Daniel J. Doherty MBChB², Ville Karhunen MSc¹, Azmil H Abdul-Rahim MBChB MD⁶, Martin Taylor-
9 Rowan PhD², Verena Zuber PhD^{1,3}, Philip S. Tsao PhD^{7,8}, Derek Klarin MD⁹⁻¹², VA Million Veteran
10 Program, Evangelos Evangelou PhD^{1,13}, Paul Elliott FMedSci^{1,14-17}, Scott M. Damrauer MD^{18,19},
11 Terence J Quinn MBChB², Abbas Dehghan MD PhD^{1,14,15}, Evropi Theodoratou PhD^{5,20†}, Jesse Dawson
12 MBChB PhD^{2†}, Ioanna Tzoulaki PhD^{1,13-15†}

13 *These authors contributed equally and are joint first

14 †These authors contributed equally and are joint last

15 16 Affiliations

17 ¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
18 London, UK.

19 ²Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.

20 ³MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK.

- 1 ⁴Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of
- 2 Cambridge, Cambridge, UK.
- 3 ⁵Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
- 4 ⁶Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK.
- 5 ⁷VA Palo Alto Health Care System, California, USA.
- 6 ⁸Department of Medicine, Stanford University School of Medicine, California, USA.
- 7 ⁹Malcom Randall VA Medical Center, Gainesville, Florida, USA.
- 8 ¹⁰Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School,
- 9 Massachusetts, USA.
- 10 ¹¹Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Massachusetts,
- 11 USA.
- 12 ¹²Division of Vascular Surgery and Endovascular Therapy, University of Florida School of Medicine,
- 13 Gainesville, Florida, USA.
- 14 ¹³Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina,
- 15 Greece.
- 16 ¹⁴MRC Centre for Environment and Health, School of Public Health, Imperial College London, London,
- 17 UK.
- 18 ¹⁵UK Dementia Research Institute at Imperial College London, London, UK.
- 19 ¹⁶Imperial Biomedical Research Centre, Imperial College London and Imperial College NHS
- 20 Healthcare Trust, London, UK.
- 21 ¹⁷Health Data Research UK-London, London, UK.
- 22 ¹⁸Corporal Michael J. Crescenz VA Medical Center, Philadelphia, USA.

1 ¹⁹Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia,
2 USA.

3 ²⁰Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of
4 Edinburgh, Edinburgh, United Kingdom.

5 **Corresponding author**

6 Dr Dipender Gill

7 Department of Epidemiology and Biostatistics, School of Public Health, Medical School Building, St

8 Mary's Hospital, Imperial College London, United Kingdom, W2 1PG

9 Telephone: +44 (0) 7904843810

10 Fax: +44 (0) 20 3313 8223

11 E-mail: dipender.gill@imperial.ac.uk

12

13 Total word count: 4,845

1 Abstract (250 words)

2 **Aims:** To investigate the effect of serum urate on blood pressure and cardiovascular disease (CVD)
3 risk by updating evidence from Mendelian randomization (MR) analysis and meta-analysis of
4 randomized controlled trials (RCTs).

5 **Methods and Results:** Using recently available data from the Million Veterans Program and UK
6 Biobank, the main MR analyses showed that every 1-standard deviation increase in genetically
7 predicted serum urate was associated with an increased risk of coronary heart disease (odds ratio
8 1.19, 95% confidence interval 1.10-1.30, $P=4 \times 10^{-5}$), peripheral artery disease (1.12, 95%CI 1.03 to
9 1.21, $P=9 \times 10^{-3}$), and stroke (1.11, 95%CI 1.05 to 1.18, $P=2 \times 10^{-4}$). In MR mediation analyses, SBP was
10 estimated to mediate approximately one third the effect of urate on CVD risk. Systematic review and
11 meta-analysis of RCTs showed a favorable effect of urate-lowering treatment on SBP (mean
12 difference -2.55mmHg, 95%CI -4.06 to -1.05, $P=1 \times 10^{-3}$) and major adverse cardiovascular events
13 (MACE) in those with previous CVD (OR 0.40, 95%CI 0.22 to 0.73, $P=3 \times 10^{-3}$), but no significant effect
14 on MACE in all individuals (OR 0.73, 95%CI 0.48 to 1.09, $P=0.12$).

15 **Conclusion:** MR and clinical trial data support an effect of higher serum urate on increasing blood
16 pressure, which may mediate a consequent effect on CVD risk. High-quality trials are necessary to
17 provide definitive evidence on the specific clinical contexts where urate-lowering may be of
18 cardiovascular benefit.

19 **Key words:** urate, cardiovascular disease, blood pressure, Mendelian randomization, systematic
20 review.

1 Introduction

2 Urate is a breakdown product of purine metabolism. Its raised levels have been associated with a
3 number of adverse health outcomes including gout, hypertension and cardiovascular disease (CVD)
4 (1). However, it remains unclear whether these associations represent causal effects (2, 3). The
5 relationship between serum urate, obesity, diet and other cardiovascular risk factors raises
6 considerable potential for confounding and reverse causation (4).

7 Pre-clinical studies support a causal role for urate in hypertension (5). Randomized controlled trial
8 (RCT) data have shown that both allopurinol and probenecid reduce systolic blood pressure (SBP) in
9 hyperuricemic adolescents (1, 6, 7). Pooling of all available trial data can offer more precise effect
10 estimates for the effect of urate-lowering therapy on blood pressure (8). As elevated blood pressure
11 is a risk factor for CVD, it is important to clarify any role of SBP in mediating an effect of urate on
12 cardiovascular outcomes.

13 The genetic determinants of serum urate levels have been increasingly well-characterized (4). This
14 has made it possible to identify better instruments for Mendelian randomization (MR) analyses
15 investigating the effect of genetically predicted serum urate on cardiovascular outcomes than in
16 previous efforts (3, 9-11). The use of variants randomly allocated at conception to proxy the effect of
17 modifying serum urate means that MR is less susceptible to the environmental confounding,
18 measurement error and reverse causation bias that can limit causal inference in traditional
19 epidemiological approaches.

20 The aim of the current study was to perform MR analyses investigating the effect of genetically
21 predicted urate levels on SBP and CVD risk using contemporary data, and compare findings with
22 results obtained from updated systematic review and meta-analysis of urate-lowering RCTs.

1 **Methods**

2 **Two-sample Mendelian randomization**

3 The MR analyses have been reported as per the STROBE-MR guidelines (Supplementary Checklist 1)
4 (12).

5 ***Genetic association estimates***

6 Genetic association estimates for serum urate in two-sample MR were obtained by using PLINK
7 software to meta-analyze summary data from GWAS analyses of 110,347 European-ancestry
8 individuals and 343,836 White British UK Biobank participants respectively (13-15). Urate estimates
9 in MR analyses are provided per 1-standard deviation (SD), which corresponds to 80.3 μ mol/L. For
10 consideration of SBP as a mediator in the two-sample multivariable MR, genetic association
11 estimates were obtained from a GWAS of 317,195 White British UK Biobank participants, where SBP
12 was measured using automated readings with correction made for any anti-hypertensive drug use
13 by adding 10mmHg to the measured reading (16). In contrast, when investigating SBP as an
14 outcome, genetic association estimates were obtained from the International Consortium for Blood
15 Pressure (ICBP) GWAS analysis of 287,245 European-ancestry individuals (excluding UK Biobank
16 participants) (17). A different population was considered when studying SBP as an outcome to avoid
17 overlap with the UK Biobank participants used to obtain genetic association estimates for urate, as
18 this can bias MR estimates (18). SBP estimates are provided per 1-SD increase, which corresponds to
19 18.6mmHg. Genetic association estimates for CHD were obtained from the CARDIoGRAMplusC4D
20 Consortium 1000G multi-ethnic GWAS (77% European-ancestry) of 60,801 cases and 123,504
21 controls, with a broad and inclusive definition of CHD applied (19). Genetic association estimates for
22 PAD were obtained from the Million Veterans Program (MVP) multi-ethnic (72% European-ancestry)
23 GWAS of 31,307 cases and 211,753 controls, with case definitions made using hospital diagnosis and
24 procedure codes (20). Genetic association estimates for stroke were obtained from the
25 MEGASTROKE multi-ethnic (86% European-ancestry) GWAS of 67,162 cases and 454,450 controls
26 (21), with the stroke definition including both ischemic and hemorrhagic etiologies.

1 Genetic variants used as instruments

2 Genetic instruments for the two-sample MR were identified as single-nucleotide polymorphisms
3 (SNPs) that were associated with urate (or SBP, in mediation analyses) at genome-wide significance
4 ($P < 5 \times 10^{-8}$) and were in pair-wise linkage disequilibrium (LD) with $r^2 < 0.001$. Clumping was performed
5 using the TwoSampleMR package of R (22). For univariable MR, instrument strength was estimated
6 using the *F*-statistic, with variance in the exposure explained assessed using the R^2 value (23).

7 Statistical analysis

8 In all analyses, SNPs were aligned by their effect alleles and no additional consideration was made
9 for palindromic variants. Two-sample MR analyses were performed to investigate the effect of
10 genetically predicted serum urate on CHD, PAD, stroke and SBP respectively. A Bonferroni threshold
11 ($P < 0.01$) that corrected for multiple testing related to the four outcomes was used to ascertain
12 statistical significance in the main analysis. Inverse-variance weighted MR was used in the main
13 analysis, with the simple median (24), contamination-mixture method (25), Egger (26), PRESSO (27)
14 and multivariable MR (28) (only for CVD outcomes) sensitivity analyses used to explore the
15 robustness of the findings to potential pleiotropy of the genetic variants. Given the previously
16 demonstrated overlap in the genetic determinants of urate with other metabolic traits (4), the
17 multivariable MR sensitivity analysis adjusted for genetic associations of the instruments with body
18 mass index (BMI), estimated glomerular filtration rate, type 2 diabetes mellitus, serum low-density
19 lipoprotein cholesterol, serum high-density lipoprotein cholesterol and serum triglycerides together
20 in the same model. Such multivariable MR was not performed when considering SBP as an outcome,
21 due to population overlap with the cohorts used to obtain genetic association estimates for the
22 metabolic exposures (18). In MR mediation analyses, multivariable MR was applied in the two-
23 sample setting to adjust for the genetic association of the instruments with SBP, and network MR
24 was used to estimate the proportion of the total effect of urate on each cardiovascular outcome that
25 is mediated through SBP (29). Standard errors were estimated using the propagation of error
26 method. Further details on these analyses are provided in the Supplementary Methods.

1 Genetic association estimates, instruments and statistical analyses for the one-sample MR are
2 detailed in the Supplementary Methods.

3 **Systematic review and meta-analysis of randomized controlled trials**

4 The systematic review was conducted in accordance with the recommendations from the Preferred
5 Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement (Supplementary
6 Checklist 2) (30). The study protocol was registered and published in the International Prospective
7 Register of Systematic Reviews (PROSPERO: CRD42020164589).

8 ***Inclusion and exclusion criteria***

9 RCTs of pharmacological urate-lowering versus placebo or no treatment of duration ≥ 28 days in
10 patients ≥ 18 years of age were eligible. Studies with co-intervention that was inconsistent between
11 intervention and control groups, or with mixed experimental groups were excluded.

12 ***Data sources and searches***

13 We conducted a systematic search of multidisciplinary databases across four electronic platforms:
14 Medline (OVID), EMBASE (OVID), Web of Science (Thomson Reuters) and Cochrane Library
15 (Cochrane). Studies published from 1 January 2016 to 30 September 2019 were considered. The
16 literature search terms matched those used in a previous systematic review (Supplementary
17 Methods) (7). No language restrictions were applied. Reference lists of retrieved articles were
18 reviewed to identify additional relevant articles. Data were included from studies in previous
19 systematic reviews investigating the effects of urate lowering therapy on SBP (searches until 29 June
20 2016) (8), and CVD (searches until 30 December 2016) (7).

21 ***Data extraction***

22 Study details and results were extracted using a pre-designed template. In the case of cross-over
23 trials, only data from the first study period (before cross-over) were used. Risk of bias was assessed
24 in accordance with the Cochrane guidelines (31). All aspects of database search, study selection,

1 data extraction and risk of bias assessment were performed independently by two investigators
2 (ACC and DJD), with arbitration to a third investigator (AHA-R) as necessary.

3 **Outcomes**

4 The outcomes considered in systematic review and meta-analysis of RCTs were SBP and risk of major
5 adverse cardiovascular event (MACE; cardiovascular death, non-fatal myocardial infarction, unstable
6 angina requiring urgent revascularization, or non-fatal stroke). In secondary analysis, we also
7 considered MACE in patients with prior CVD, as this would likely represent a higher risk population
8 with greater statistical power.

9 **Statistical analysis**

10 Analysis of extracted data was based on modified intention-to-treat (considering patients who
11 received at least one dose of the allocated treatment) or intention-to-treat results. If not reported,
12 the mean change in SBP pre- and post-treatment was calculated and the SD was imputed using the
13 propagation of error method using a correlation coefficient that was derived from the largest study
14 in the meta-analysis that reported SD for SBP values at baseline, at end of the study and for the
15 change in SBP (31, 32). The measure of effect size was the difference in mean SBP, defined as the
16 mean difference between patients treated with urate lowering therapy versus control. A negative
17 value of the difference in mean SBP indicates a greater reduction of SBP in the urate lowering
18 therapy group as compared to the control group. Overall CVD risk estimates are described in terms
19 of odds-ratio (OR).

20 Random-effects inverse-variance weighted meta-analysis was used to pool estimates from different
21 studies, and study heterogeneity was assessed using the I-squared (I^2) statistic. Sensitivity analyses
22 were conducted including only studies at low risk of bias. For the analysis considering SBP as an
23 outcome, meta-regression was performed to assess the effect of baseline SBP on treatment
24 response. Analyses were conducted using Comprehensive Meta-Analysis software version 3 (Biostat,
25 USA).

1 Ethical approval, data availability and reporting

2 All data used in this work are either publicly accessible or available on request from their original
3 studies, which obtained appropriate patient consent and ethical approval. The UK Biobank data were
4 accessed through application 236. All results generated in this work are presented in either the
5 manuscript or its supplementary files.

6 Results

7 Mendelian randomization

8 The instruments for urate that were used in the two-sample MR are presented in Supplementary
9 Table 2. The main IVW MR showed that higher genetically predicted serum urate levels were
10 associated with an increased risk of CHD, with odds ratio (OR) per 1-SD increase in genetically
11 predicted urate 1.19, 95% confidence interval (95%CI) 1.10-1.30, $P=4 \times 10^{-5}$. Consistent results were
12 obtained in all MR sensitivity analyses except MR-Egger, which had wide 95%CI (Figure 1). Higher
13 genetically predicted serum urate was also associated with increased risk of both PAD (OR 1.12,
14 95%CI 1.03-1.21, $P=9 \times 10^{-3}$) and stroke (OR 1.11, 95%CI 1.05-1.18, $P=2 \times 10^{-4}$) in the main IVW analysis,
15 with similar results obtained in all MR sensitivity analyses except MR-Egger, which again had wide
16 95%CI (Figure 1). For the multivariable MR adjusting for genetic confounding through BMI,
17 estimated glomerular filtration rate, type 2 diabetes and lipid traits, direct effects of these exposures
18 on risk of the respective CVD outcomes are presented in Supplementary Table 3. Considering SBP,
19 the main IVW and sensitivity MR analyses all provided supporting evidence of a causal effect of
20 serum urate (IVW estimate in SD units per 1-SD increase in genetically predicted urate 0.09, 95%CI
21 0.05-0.12, $P=6 \times 10^{-7}$; Figure 2). Scatter plots depicting the association of the instrument variants with
22 serum urate and the respective outcomes are presented in Supplementary Figures 1-4.

23 Performing multivariable MR to adjust for genetically predicted SBP showed attenuation of the urate
24 effect estimates for the CVD outcomes as compared to the main IVW univariable MR (Figure 3),
25 supporting that part of the effect of urate on these outcomes is mediated through SBP. Network MR

1 mediation analysis quantified this as 29% (95%CI 9%-48%) for CHD, 44% (95%CI 5%-83%) for PAD
2 and 45% (95%CI 14%-76%) for stroke. For CHD there remained evidence of a direct effect of urate
3 even after adjusting for SBP (OR 1.13, 95%CI 1.03-1.23, $P=0.01$). In contrast for PAD and stroke,
4 although the estimate for the direct effect of urate that is not mediated through SBP was positive,
5 the confidence interval crossed the null and the results were not statistically significant (PAD OR
6 1.08, 95%CI 1.00-1.17, $P=0.07$; stroke OR 1.06, 95%CI 0.99-1.12, $P=0.10$). Direct effects of SBP on the
7 outcomes after adjusting for genetically predicted serum urate are presented in Supplementary
8 Table 4.

9 The results of the one-sample MR analysis were consistent with the above-mentioned two-sample
10 MR analysis and are detailed in the Supplementary Results, Supplementary Tables 5-8 and
11 Supplementary Figure 5.

12 **Systematic review and meta-analysis of randomized controlled trials**

13 In total, 95 studies were eligible for the systematic review and meta-analysis. Regarding the updated
14 searches (1 January 2016 to 30 September 2019), 5,353 records were screened, 30 full texts were
15 assessed for eligibility and 13 studies were identified that fulfilled the eligibility criteria
16 (Supplementary Figure 6). Characteristics of included studies that were identified in the updated
17 search are presented in Supplementary Table 9.

18 The primary analysis of effects on SBP included 15 studies (Supplementary Figure 7). There was
19 heterogeneity between these studies (I^2 89%), which was mostly attributable to one study
20 considering renal dialysis patients (Supplementary Figure 7) (33). Excluding this study, subjects
21 treated with urate-lowering therapy had greater reduction in SBP than subjects in the control group
22 (mean difference in SBP -2.55, 95%CI -4.06 to -1.05, $P=1 \times 10^{-3}$, I^2 43%) (Figure 4). The analysis of
23 MACE risk in all patients considered 88 studies, of which 24 had events (Figure 5), and the analysis of
24 MACE risk in patients with prior cardiovascular events considered 10 studies, of which 7 had events
25 (Figure 6). Urate-lowering therapy was not significantly associated with risk of MACE in all patients

(OR 0.73, 95%CI 0.48 to 1.09, $P=0.12$, I^2 0%), but was significantly associated with reduction in risk of MACE in patients with a prior cardiovascular event (OR 0.40, 95%CI 0.22 to 0.73, $P=3 \times 10^{-3}$, I^2 0%). Risk of bias was low in 23 of the 95 included studies (Supplementary Table 10). Risk of bias was low in 4 out of the 15 studies investigating effects on SBP, 20 out of the 24 studies investigating MACE in all patients, and 4 out of the 7 studies investigating MACE in patients with a prior cardiovascular event. In sensitivity analyses including only studies at low risk bias, urate lowering therapy was associated with greater SBP lowering compared to control (mean difference in SBP -2.89, 95%CI -5.37 to -0.41, $P=0.02$, I^2 49%; Supplementary Figure 8), but was not significantly associated with risk of MACE in all patients (OR 0.64, 95%CI 0.28 to 1.46, $P=0.29$, I^2 0%; Supplementary Figure 9) or in patients with a prior cardiovascular event (OR 0.59, 95%CI 0.18 to 1.91, $P=0.38$, I^2 0%; Supplementary Figure 10). Meta-regression analysis demonstrated no effect of baseline SBP on treatment response to urate lowering therapy (coefficient -0.01, 95%CI -0.19 to 0.17, $P=0.92$; Supplementary Figure 11).

Discussion

We used a comprehensive framework of MR methodologies to perform detailed investigation into the association of genetically predicted serum urate with CVD outcomes, and replicated findings in the independent UK Biobank population. The MR analyses identified consistent evidence of an effect of higher genetically predicted serum urate levels on risk of CVD and SBP. Performing multivariable MR to adjust for genetic association with SBP attenuated the estimates for the CVD outcomes to support that at least some of the effect of urate may be mediated through raised blood pressure. Updated systematic review and meta-analysis of RCT data similarly showed a favorable effect of urate-lowering treatment on SBP, with some evidence to also support a protective effect on MACE risk in individuals with prior CVD, but not in all individuals. Hyperuricemia has been postulated to cause endothelial dysfunction by increasing oxidative stress (1), and this could directly increase risk of CVD through effects on the vascular endothelium (1). In an

1 animal model where hyperuricemia was induced using a uricase inhibitor, hypertension followed
 2 after three weeks while controls remained normotensive (5), thus representing a second mechanism
 3 by which urate can increase risk of CVD. The results of the Febuxostat and Allopurinol Streamlined
 4 Trial (FAST) and the Allopurinol and cardiovascular outcomes in patients with ischemic heart disease
 5 (ALL-HEART) trials will help provide further insight on potential re-purposing of existing urate-
 6 lowering agents for CVD prevention (34, 35). Allopurinol could represent an inexpensive, safe and
 7 well-tolerated drug for reducing cardiovascular risk (36).

8 Our current study has several strengths. We triangulate evidence across MR analyses and RCT data
 9 to provide consistent evidence for a role of serum urate in increasing SBP and potentially also
 10 increasing CVD risk. Our analyses identify a possible mediating role of SBP in the pathway from
 11 serum urate to CVD risk. In contrast, previous MR studies have considered associations of the
 12 genetic instruments for urate with blood pressure as representing genetic confounding (3, 9-11).
 13 Exclusion of such variants or adjustment for their genetic association with blood pressure traits, as
 14 was done in these studies (3, 9-11), would obscure any true causal effect of genetically predicted
 15 urate on cardiovascular disease risk. Our present MR analysis also incorporated more powerful
 16 instruments for serum urate than were available previously. The variants used as instruments in our
 17 one-sample MR analysis of UK Biobank participants explained approximately 7.7% of the variance in
 18 serum urate (4), in contrast to the 5.3% explained when selecting instrument variants from the
 19 previous largest published GWAS of serum urate (13). Similarly, our systematic review and meta-
 20 analysis of RCTs updated evidence from previous efforts to consider an additional 13 studies (7, 8).

21 Our work also has limitations. The MR approach makes a series of modelling assumptions, and in
 22 particular requires that the genetic variants used as instruments do not affect the considered
 23 outcomes through pathways that are independent of urate. While this can never be completely
 24 excluded, we performed a range of MR sensitivity analyses that make distinct assumptions on the
 25 presence of pleiotropic variants and generally found consistent estimates. The MR-Egger method

1 generated wide 95% CIs in all analyses and was likely of limited reliability due to the strength of the
2 urate instruments being correlated to their direct effects on the CVD outcomes under consideration
3 (4, 37). The majority (71 out of 94) RCTs considered in our meta-analysis had a high or undetermined
4 risk of bias and there was heterogeneity in the results of RCTs measuring change in SBP following
5 urate-lowering therapy, possibly related to study design, in turn limiting the strength of conclusions
6 that can be drawn. Finally, we investigated SBP in mediating the effect of urate on CVD outcomes,
7 rather than diastolic blood pressure. These two traits are highly genetically and phenotypically
8 correlated (17), and it follows that a similar mediating role may be found for diastolic blood
9 pressure.

10 To summarize, we have found consistent MR and RCT evidence for an effect of higher serum urate
11 levels on increasing SBP, with further evidence also supporting a potential effect on risk of CVD.
12 High-quality trial data are now necessary to provide definitive evidence on the specific clinical
13 contexts where urate-lowering may be of cardiovascular benefit, with some large-scale studies
14 already underway (34, 35).

1 Contributors

2 DG, JD, ACC, ET and IT designed the study. DG, XL, ACC, DD, AHA-R and MT-R had full access to the
3 data and performed the analysis. All authors interpreted the results. DG, JD, ACC and IT drafted the
4 manuscript. All authors critically revised the manuscript for intellectual content. All authors
5 approved the submitted version and are accountable for the integrity of the work.

7 Sources of Funding

8 This work was supported by funding from the US Department of Veterans Affairs Office of Research
9 and Development, Million Veteran Program Grant MVP003 (I01-BX003362). This publication does
10 not represent the views of the Department of Veterans Affairs of the US Government. DG is funded
11 by the Wellcome 4i Clinical PhD Program at Imperial College London (203928/Z/16/Z). VK is funded
12 by the European Union's Horizon 2020 research and innovation program under the Marie
13 Skłodowska-Curie grant (721567). PE acknowledges support from the Medical Research Council
14 (MR/S019669/1), the National Institute for Health Research Imperial Biomedical Research Centre,
15 Imperial College London (RDF03), the UK Dementia Research Institute (DRI) at Imperial College
16 London funded by UK DRI Ltd (funded by Medical Research Council, Alzheimer's Society, Alzheimer's
17 Research UK), and Health Data Research (HDR) UK London funded by HDR UK Ltd (funded by a
18 consortium led by the Medical Research Council 1004231). SMD was supported by the Department
19 of Veterans Affairs Office of Research and Development (IK2-CX001780). ET is funded by a Cancer
20 Research UK Career Development Fellowship (C31250/A22804). The MEGASTROKE project received
21 funding from sources specified at <http://www.megastroke.org/acknowledgments.html>. Details of all
22 MEGASTROKE authors are available at <http://www.megastroke.org/authors.html>.

23

1 **Acknowledgements**

2 The authors acknowledge the contributors of the data used in this work: CARDIoGRAMplusC4D,
 3 CKDGen, DIAGRAM, Genetic Investigation of ANthropometric Traits, Global Lipids Genetics
 4 Consortium, International Consortium for Blood Pressure, MEGASTROKE, Million Veterans Program
 5 and UK Biobank.

6

7 **Disclosures**

8 DG is employed part-time by Novo Nordisk. JD and TQ have received charitable research income to
 9 conduct clinical trials of allopurinol use in people with stroke. The remaining authors have no
 10 conflicts of interest to declare.

References

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med*. 2008;359(17):1811-21.
2. Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. *BMJ*. 2017;357:j2376.
3. Li X, Meng X, He Y, Spiliopoulou A, Timofeeva M, Wei WQ, et al. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. *PLoS Med*. 2019;16(10):e1002937.
4. Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. *Nat Genet*. 2019.
5. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension*. 2001;38(5):1101-6.
6. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. *JAMA*. 2008;300(8):924-32.
7. Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d'Avila R, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord*. 2018;18(1):24.
8. Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. *Ann Med*. 2017;49(2):142-56.
9. Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. *J Am Coll Cardiol*. 2016;67(4):407-16.

- 1 10. Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically Determined Uric Acid and
2 the Risk of Cardiovascular and Neurovascular Diseases: A Mendelian Randomization Study of
3 Outcomes Investigated in Randomized Trials. J Am Heart Assoc. 2019;8(17):e012738.
- 4 11. White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, et al. Plasma urate concentration and
5 risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol.
6 2016;4(4):327-36.
- 7 12. Davey Smith G, Davies NM, Dimou N, Egger M, Gallo V, Golub R, et al. STROBE-MR:
8 Guidelines for strengthening the reporting of Mendelian randomization studies.
9 <https://doi.org/10.7287/peerj.preprints.27857v1>. PeerJ Preprints. 2019;7:e27857v1.
- 10 13. Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide
11 association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet.
12 2013;45(2):145-54.
- 13 14. Neale Lab. Accessed 2019 January 16. Rapid GWAS of thousands of phenotypes for 337,000
14 samples in the UK Biobank 2018. [http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-](http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank)
15 [of-phenotypes-for-337000-samples-in-the-uk-biobank](http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank).
- 16 15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set
17 for whole-genome association and population-based linkage analyses. Am J Hum Genet.
18 2007;81(3):559-75.
- 19 16. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. Understanding the
20 consequences of education inequality on cardiovascular disease: mendelian randomisation study.
21 BMJ. 2019;365:l1855.
- 22 17. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic
23 analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat
24 Genet. 2018;50(10):1412-25.
- 25 18. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample
26 Mendelian randomization. Genet Epidemiol. 2016;40(7):597-608.

- 1 19. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000
2 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet.
3 2015;47(10):1121-30.
- 4 20. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, et al. Genome-wide association
5 study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019;25(8):1274-9.
- 6 21. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry
7 genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and
8 stroke subtypes. Nat Genet. 2018;50(4):524-37.
- 9 22. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform
10 supports systematic causal inference across the human phenome. eLife. 2018;7.
- 11 23. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. Using
12 multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med
13 Res. 2012;21(3):223-42.
- 14 24. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
15 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
16 Epidemiol. 2016;40(4):304-14.
- 17 25. Burgess S, Foley CN, Allara E, Staley JR, Howson JM. A robust and efficient method for
18 Mendelian randomization with hundreds of genetic variants: unravelling mechanisms linking HDL-
19 cholesterol and coronary heart disease. bioRxiv. 2019:566851.
- 20 26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
21 effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.
- 22 27. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal
23 relationships inferred from Mendelian randomization between complex traits and diseases. Nat
24 Genet. 2018;50(5):693-8.
- 25 28. Burgess S, Dudbridge F, Thompson SG. Re: "Multivariable Mendelian randomization: the use
26 of pleiotropic genetic variants to estimate causal effects". Am J Epidemiol. 2015;181(4):290-1.

- 1 29. Carter AR, Sanderson E, Hammerton G, Richmond RC, Smith GD, Heron J, et al. Mendelian
2 randomisation for mediation analysis: current methods and challenges for implementation. *bioRxiv*.
3 2019:835819.
- 4 30. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic
5 reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
- 6 31. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for
7 trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of
8 Interventions. *Cochrane Database Syst Rev*. 2019;10:ED000142.
- 9 32. McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of Uric Acid Lowering on Renin-
10 Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial. *Clin J Am Soc*
11 *Nephrol*. 2017;12(5):807-16.
- 12 33. Omrani H, Muhammad S, Sadeghi K, Raeisi D, Hashemian A. The effect of allopurinol
13 treatment regimen on serum uric acid and arterial blood pressure in hemodialysis patients. *J*
14 *Kermanshah Univ Med*. 2016;20:56-61.
- 15 34. MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, et al. Protocol of the
16 Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open,
17 blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the
18 management of symptomatic hyperuricaemia. *BMJ Open*. 2014;4(7):e005354.
- 19 35. Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, et al. Multicentre, prospective,
20 randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving
21 cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.
22 *BMJ Open*. 2016;6(9):e013774.
- 23 36. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on
24 exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.
25 *Lancet*. 2010;375(9732):2161-7.

- 1 37. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-
2 Egger method. Eur J Epidemiol. 2017;32(5):377-89.
3

Figures

Figure 1 - Mendelian randomization estimates for the effect of 1-standard deviation (SD) increase in genetically determined serum urate levels on risk of coronary heart disease (CHD), peripheral artery disease (PAD) and stroke.

CI: confidence interval; Con-Mix: contamination-mixture; IVW: inverse-variance weighted; MVMR: multivariable Mendelian randomization (adjusting for genetic association of the instrument variants with body mass index, estimated glomerular filtration rate, type 2 diabetes mellitus, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides); OR: odds ratio; PRESSO: pleiotropy residual sum and outlier. The outlier-corrected PRESSO results are presented (five outlier variants were identified for CHD, eight for PAD, and one for stroke). The Egger intercept was

1 0.005 (95% CI 0.001-0.009, $P=0.004$) for CHD, 0.005 (95% CI 0.001-0.009, $P=0.003$) for PAD and 0.001

2 (95% CI -0.001-0.003, $P=0.24$) for stroke.

1 **Figure 2 – Mendelian randomization estimates for the effect of 1-standard**
2 **deviation (SD) increase in genetically determined serum urate levels on**
3 **systolic blood pressure.**

4
5 *CI: confidence interval; Con-Mix: contamination-mixture; IVW: inverse-variance weighted;*
6 *OR: odds ratio; PRESSO: pleiotropy residual sum and outlier. The outlier-corrected PRESSO results are*
7 *presented (21 outlier variants were identified). The Egger intercept was 0.002 (95% CI 0.0004-0.003,*
8 *P=0.02)*

1 **Figure 3 – Inverse-variance weighted (IVW) and multivariable Mendelian**
2 **randomization (MVMR) estimates for the effect of 1-standard deviation (SD)**
3 **increase in genetically determined serum urate levels on risk of coronary heart**
4 **disease (CHD), peripheral artery disease (PAD) and stroke. The MVMR analysis**
5 **adjusts for the association of the genetic instruments with systolic blood**
6 **pressure.**

CI: confidence interval; OR: odds ratio.

- 1 **Figure 4 – Forest plot of randomized controlled trial estimates for change in**
- 2 **mean systolic blood pressure in non-renal dialysis patients receiving urate-**

- 3 **lowering therapy or placebo/no treatment.**

4 I^2 heterogeneity statistic: 43%. CI: confidence interval

- 1 **Figure 5 – Forest plot of randomized controlled trial estimates for risk of major**
- 2 **adverse cardiovascular events in all patients receiving urate-lowering therapy**

- 3 **or placebo/no treatment.**

4 I^2 heterogeneity statistic: 0%. CI: confidence interval.

- 1 **Figure 6 – Forest plot of randomized controlled trial estimates for risk of major**
- 2 **adverse cardiovascular events in patients with existing cardiovascular disease**

- 3 **receiving urate-lowering therapy or placebo/no treatment.**

4 I^2 heterogeneity statistic: 0%. CI: confidence interval.